VECT — VectivBio Holding AG Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousMid Cap
Brief: Vectivbio Reports Positive Interim Clinical Data From Stars Nutrition, A Phase 2 Study Investigating Apraglutide In Short Bowel Syndrome With Intestinal Failure Patients
Brief: Cingulate reports Q2 results
U.S. STOCKS ON THE MOVE-Boeing, 180 Life Sciences, VectivBio Holding
VectivBio slides on equity raise
Brief: Vectivbio Announces Pricing Of $30 Million Public Offering Of Ordinary Shares
Brief: Vectivbio Announces Launch Of Public Offering Of Ordinary Shares
Brief: Vectivbio Announces First Two Patients Dosed In Phase 2 Stargaze Study Of Apraglutide For The Treatment Of Acute Graft-Versus-Host Disease
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:32 PM
Brief: Vectivbio Holding AG Files For Mixed Shelf Of Up To $200 Million- SEC Filing
BofA cuts VectivBio PT on likely higher near-term costs
Brief: VectivBio Reports Full Year 2021 Financial Results And Provides Business Update
VectivBio Holding AG expected to post a loss of 64 cents a share - Earnings Preview
Brief: VectivBio Announces Japan License Deal And Loan Facility Agreement, Providing Up To $117 Million To Fuel Company Through Key Catalysts
Brief: VectivBio Presents Data Supporting Apraglutide For Treatment Of SBS-IF Patients With Renal Dysfunction
Brief: VectivBio Presents Preclinical Data Supporting Apraglutide For Treatment Of Acute Graft-Versus-Host Disease At 48Th Annual Meeting Of European Society For Blood And Marrow Transplantation
U.S. STOCKS ON THE MOVE-Rivian, Darden Restaurants, General Motors, FedEx
U.S. STOCKS ON THE MOVE-Rivian, FedEx, General Motors, Cerner
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:38 PM
Brief: Vectivbio Holding AG Announces Successful Opening Of US IND For Apraglutide For Acute Graft-Versus-Host Disease